[Neoadjuvant chemotherapy for esophageal cancer by administration of nedaplatin alone].

Abstract

The possibility of safe implementation of neoadjuvant chemotherapy using nedaplatin (254-S) was investigated with the aim of improving the therapeutic results in advanced esophageal cancer patients. The subjects had usually undergone two courses of 254-S, 80 or 100 mg/m2, preoperatively, at intervals of 4 weeks. After chemotherapy, responses were evaluated, and resection was undertaken 4 weeks after the final administration. The subjects were 10 patients with untreated esophageal cancer. As a result of evaluation of responses of main lesions to chemotherapy, a partial response (PR) was observed in 3 patients, and a minor response 3, showing an efficacy rate of 30%. Pathological findings before treatment were determined by staining of a cell cycle marker (Ki-67). The 3 patients who were evaluated as PR (clinical efficacy) showed high rates of positivity for Ki-67 of 47.4%, 52.7%, and 86%, respectively. There were no serious complications and no death related to operation. The observations suggested that 254-S, which has little or no side effects including nephrotoxicity, can become the standard remedy for esophageal cancer instead of CDDP in future.

• Authors: S Hirata, E Yatsuyanagi, H Yamazaki, Y Sugimoto, S Kosiko, T Kokubo, Y Atsuta, T Sasajima, N Miyokawa
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 27 Issue 2 Pg. 221-6 (Feb 2000) ISSN: 0385-0684 [Print] Japan
• PMID: 10700891 (Publication Type: English Abstract, Journal Article)

Chemical References

• Antineoplastic Agents
• Ki-67 Antigen
• Organoplatinum Compounds
• Tumor Suppressor Protein p53
• nedaplatin

Topics

• Aged
• Antineoplastic Agents (administration & dosage)
• Cell Cycle
• Drug Administration Schedule
• Esophageal Neoplasms (blood, drug therapy, pathology)
• Female
• Humans
• Ki-67 Antigen (blood)
• Male
• Middle Aged
• Neoadjuvant Therapy
• Organoplatinum Compounds (administration & dosage)
• Preoperative Care
• Tumor Suppressor Protein p53 (blood)